Early Use of Long-acting Tacrolimus in Lung Transplant Recipients

January 8, 2024 updated by: Anil Trindade, Vanderbilt University Medical Center

A Prospective, Randomized, Controlled Pilot Study of Early-Use Long Acting Tacrolimus (Envarsus XR) in Lung Transplant Recipients

Lung transplantation is a life-saving therapy for patients with advanced lung disease, however, necessitates the use of life-long immunosuppressive therapy for the prevention of acute and chronic rejection. The backbone of immunosuppression is the calcineurin-inhibitor class, with tacrolimus being the preferred drug due to its potency and improved side-effect profile. Nevertheless, tacrolimus is associated with several side effects including increased risk for infection and malignancy, tremors, headaches, seizures, hypertension, leukopenia and renal dysfunction. In fact, by 6 months post-transplant, 50% of patients will have a 50% decline in eGFR and by 5 years post-transplant ~10% of patients will have advanced renal disease that may require renal replacement therapy and/or kidney transplantation. Tacrolimus induces a nephropathy in two ways- acute calcineurin inhibitor nephrotoxicity (CIN) is mediated by afferent arteriolar vasoconstriction, whereas chronic CIN is due to interstitial nephritis and fibrosis. Immunosuppressive regimens that spare or dose-reduce calcineurin inhibitors have been shown to have a modest impact on preserving renal function, but are limited by timing. Although most studies support implementing renal preserving protocols early on, this is balanced by the potential for acute cellular rejection, antibody mediated rejection and anastomotic dehiscence.

Long-acting Tacrolimus (LCP-tacrolimus) may have the potential to bridge the balance of providing potent immunosuppression, while sparing renal function, due to the better systemic dose levels and improved concentration/dose ration achieved with it compared to IR-tacrolimus, evidenced in the renal transplant population. There is limited experience with LCP-tacrolimus in lung transplantation. Several case reports chronicling the late conversion from IR-tacrolimus to LCP-tacrolimus due to absorption issues or side-effect intolerance, have demonstrated safety and tolerability. The investigators seek to determine whether early use of LCP-tacrolimus in lung transplant recipients following the index hospitalization is acceptable, and propose a single-center prospective, randomized, controlled pilot study of early-use LCP-tacrolimus in lung transplant recipients to assess safety, tolerability and side-effects of LCP-tacrolimus.

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Detailed Description

Lung transplantation is a life-saving therapy for patients with end-stage lung disease refractory to medical treatment, providing an improvement in both survival and quality of life.[1,2] Despite the benefits, patients are at risk for myriad side effects including infection, malignancy, neurologic complications (headache, tremor, seizures), gastrointestinal distress and renal failure, to name a few.[3] Many of these are related to the requisite need for life-long immunosuppression. Current standard immunosuppressive regimens for lung transplant recipients include calcineurin inhibitors (tacrolimus preferred over cyclosporine), antiproliferative agents (mycophenolate mofetil vs. azathioprine) and corticosteroids; calcineurin inhibitors serve as the backbone of immunosuppression.[4] Renal dysfunction is perhaps the most prevalent complication after lung transplantation, affecting up to 90% of post-transplant recipients.[5] By 5-year post-transplant, ~8% of patients may require renal replacement therapy and/or renal transplantation.[6] Renal dysfunction tends to occur early on in the post-transplant period. Monnier and colleagues showed in a single-center analysis that the incidence of acute kidney injury within the index hospitalization was ~75%; the median loss of glomerular function within the first year was ~45%.[7] Moreover, Canales and colleagues showed that >55% of patients in a cohort of 219 lung transplant recipients had a doubling of their pre-transplant serum creatinine, the majority occurring within the first year post-transplant.[8] Early renal dysfunction in lung transplant recipients is associated with a poor overall prognosis. Broelkroleof and colleagues demonstrated that loss of renal function within he first month post-transplant is predictive of chronic kidney disease.[9] Moreover, chronic kidney disease is associated with a five times increased risk of mortality.[5] Perhaps the greatest contributor to the development of CKD in solid-organ transplant recipients are the calcineurin inhibitors (CNIs).[10] CNIs cause renal compromise (calcineurin inhibitor nephropathy, CIN) via acute and chronic mechanisms. Acute CIN is due to potent vasoconstriction of afferent arterioles in the kidney, resulting in ischemia.[11,12] Chronic CIN is thought to be largely mediated by interstitial fibrosis as the end-result of arteriolar sclerosis, oxygen free-radical injury, and upregulation of pro-fibrotic pathways including PDGF, renin-angiotensin-aldosterone signaling, TGFB and matrix metalloproteinase-9.[11,13] Attempts at utilizing CNI-free or CNI-reduced regimens in the lung transplantation population has been understudied and/or unsuccessful to date. Belatacept, a CTLA4-fusion molecule that prevents CD28-mediated co-stimulation to activate T-lymphocytes, has been well-studied in renal transplantation as an alternative to CNIs. The BENEFIT Trial, a phase III clinical study of Belatacept vs. Cyclosporine in renal transplant recipients, demonstrated improvement in patient and allograft survival, and mean eGFR (~70 cc/min vs ~45cc/min) at seven years. However, rates of biopsy proven acute cellular rejection were twice as much with Belatacept.[14] Case reports of Belatacept as rescue therapy in lung transplant recipients intolerant of CNIs are mixed; there are reports of increased ACR and fulminant acute respiratory distress syndrome.[15,16] The mTOR inhibitor class of immunosuppression has also been incorporated into regimens in an effort to ameliorate CNI-toxicity. Villanueva and colleagues assessed outcomes of conversion to Sirolimus and reduced Tacrolimus in 49 patients with bronchiolitis obliterans syndrome (chronic rejection) or CNI-intolerance; there was no difference in renal function one year following sirolimus initiation.[17] Conversely, Shitrit and colleagues demonstrated that sirolimus plus low-dose tacrolimus led to an improvement in GFR of 10 mL/min, compared to control maintenance immunosuppression in a pilot study of sixteen lung allograft recipients.[18] More recently, Gottlieb and colleagues demonstrated that conversion to quadruple immunosuppression therapy with low-dose CNI (target tacrolimus trough 3-5) led to improvements in eGFR of 10cc/mL compared to standard immunosuppression (tacrolimus trough >5). There was no considerable difference in biopsy-proven acute rejection, chronic rejection and death.[20] The conversion for those in the 4-drug experimental group occurred on average 11 months following transplant, which may account for the muted benefit; perhaps an earlier change in immunosuppression management would have led to more clinically significant results. Notably, discontinuation rates of sirolimus in case reports are variable, with most studies reporting a 20-80% discontinuation rate due to gastrointestinal distress, pneumonitis, thrombocytopenia, etc., making the mTOR inhibitor class less appealing.[19] It is apparent that changes to immunosuppression management earlier in the post-transplant period are ideal to see a maximum benefit in preserved renal function.9 However, this is complicated by the concerns for acute cellular rejection, which has a peak incidence at 6 months post-lung transplantation.[21,22] Acute cellular rejection is a leading risk factor for the development of chronic lung allograft dysfunction (CLAD, chronic rejection).[23] Hence any dose reduction in CNI or the use of an agent associated with ACR (Belatacept) is less desirable within the first few months post-transplant.

Given the preference to utilize a CNI-based regimen early-post transplant but still minimize nephrotoxic effects, the investigators seek to determine whether the early use of long acting tacrolimus, LCP-Tacrolimus (LCP-tacro, Envarsus XR, Veloxis Pharmaceuticals), results in improved renal function compared to intermediate release tacrolimus (IR-tacrolimus, IR-tacro). Anecdotally, LCP-tacro has been used in lung transplant recipients as an alternative agent for those with debilitating headache or tremor. Early use of LCP-tacro has not been widely adopted due to perceptions associated with ability to closely titrate trough levels and cost. However, early use of LCP-tacro may provide several benefits. As a long-acting formulation, LCP-tacro allows for daily dosing. Moreover, LCP-tacro has greater absorption and bioavailability, leading to decreased swings in peak and trough concentrations; frequent fluctuations in serum tacrolimus levels potentiates afferent arteriolar vasoconstriction.[24] A steady state of systemic tacrolimus trough levels is desirable, since tacrolimus metabolism is directly related to nephrotoxicity.[25] The use of LCP-Tacro has been studied in renal transplant recipients. Langone and colleagues identified that LCP-tacrolimus compared to IR-tacrolimus was associated with improved tremor incidence and quality of life.[1] Rostaing and colleagues demonstrated that the use of LCP-tacro compared to intermediate tacrolimus was non-inferior in terms of combined death, allograft failure, biopsy-proven acute rejection and loss to follow-up. However, the use of LCP-tacro was associated with a significant reduction in total daily dose, and a 30% reduction in peak dose, without an increase in biopsy proven acute rejection episodes. Although not a prospective end-point, there was no significant impact on renal function.[26] In other studies, though, higher concentration/ drug (C/D) ratios for tacrolimus are associated with an improved renal safety profile.[27] It is conceivable that a clinical benefit of LCP-tacro over IR-tacro may be better manifested in clinical arenas that require higher target tacrolimus trough levels, such as lung allograft recipients, where initial post-transplant targets can be as high as 12-15 ng/mL, compared to renal transplantation where target trough levels are a relatively conservative 4-8 ng/mL.[2, 3] The experience of LCP-tacrolimus in the realm of lung transplantation is limited. Murakoezy and colleagues studied 53 patients that were converted from short-acting Tacrolimus to long-acting Envarsus. Conversion was performed at an average 3.6 years post-transplant. Ten patients were switched back due to side-effects (unknown), though the remainder tolerated conversion without complication. Ahmed and colleagues demonstrated feasibility in using long-acting Tacrolimus in 8 patients that were unable to achieve sufficient therapeutic levels with a short-acting formulation due to suspected polymorphisms of CYP3A4/3A5.[28] McCurry and colleagues assessed safety and feasibility of LCP-tacrolimus in a retrospective analysis of 18 lung transplant recipients. They found that patients on LCP-tacro had a 27% reduction in total dose. No patients experienced any adverse effects. Moreover, 2/18 patients had an improvement in tremors and headache.[29] Given the limited experience with of LCP-tacrolimus in lung transplant populations, the investigators propose a prospective, randomized, controlled pilot study to assess the safety, tolerability, and side-effect profile of early use LCP-tacro within the first 9 months post-transplantation. It is hypothesized that the early use of LCP-tacro in lung transplant recipients is safe and tolerable, and associated with an improved side-effect profile compared to patients treated with standard IR-tacro.

Study Type

Interventional

Enrollment (Estimated)

48

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • Tennessee
      • Nashville, Tennessee, United States, 37232
        • Vanderbilt University Medical Center
        • Contact:
        • Principal Investigator:
          • Anil J Trindade, MD
        • Sub-Investigator:
          • Haley Hoy, PhD, NP
        • Sub-Investigator:
          • Amit Parulekar, MD
        • Sub-Investigator:
          • Ivan Robbins, MD
        • Sub-Investigator:
          • Ciara Shaver, MD, PhD
        • Sub-Investigator:
          • Stephanie Norfolk, MD
        • Sub-Investigator:
          • Katie McPherson, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Status-post single or bilateral lung transplantation
  • Participant is able to give informed consent for participation in the study.
  • Male or female age 18 years or above.
  • Actively receives care at VUMC and is adherent with medical therapies.

Exclusion Criteria:

  • History of prior organ transplantation
  • History of tacrolimus use prior to transplantation
  • Intolerance of tacrolimus (that precludes use)
  • Having DSA pre-transplant (Positive virtual crossmatch)
  • Active infection with Hepatitis B or C
  • Active infection with Human Immunodeficiency Virus (HIV)
  • Baseline AST / ALT > three times upper limit normal
  • Primary graft dysfunction grade 3 at 72 hours
  • Acute kidney injury during index hospitalization that does not resolve to two times the pre-transplant baseline value.
  • Contraindication to PO (per os) intake of medications
  • Impaired GI absorption (defined as sublingual administration of IR-tacro)
  • History of frequent headaches
  • Seizure history
  • Cannot provide consent (at least verbally)
  • Pregnancy or breast-feeding
  • Participation in another interventional clinical trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Immunosuppression with Extended-Release Tacrolimus

LCP-tacrolimus administered daily to target a goal trough level of 10-14 ng/mL x 7 months (with Mycophenolate mofetil and prednisone).

Additional standard immunosuppression with either mycophenolate mofetil (500-1500mg twice daily) OR Azathioprine (up to 2mg/kg daily) AND Prednisone (5-10mg daily) will be administered.
Drug: Tacrolimus Extended Release Oral Tablet [Envarsus]
Immunosuppression regimen with Tacrolimus Extended Release as the backbone.
Other Names:
  • Envarsus XR
Drug: Mycophenolate Mofetil Hydrochloride
Standard immunosuppression of the anti-proliferative class.
Other Names:
  • CellCept
  • MMF
Drug: Prednisone
Standard immunosuppression (corticosteroid class).
Other Names:
  • Deltasone
Drug: Azathioprine
Standard immunosuppression of the anti-proliferative class.
Other Names:
  • Imuran
Active Comparator: Immunosuppression with Intermediate Release Tacrolimus

IR-tacrolimus administered twice daily to target a goal trough level of 10-14 ng/mL x 7 months (with Mycophenolate mofetil and prednisone). This is currently the standard of care at Vanderbilt University Medical Center and most other lung transplant centers (ISHLT Registry 2019).

Additional standard immunosuppression with either mycophenolate mofetil (500-1500mg twice daily) OR Azathioprine (up to 2mg/kg daily) AND Prednisone (5-10mg daily) will be administered.
Drug: Mycophenolate Mofetil Hydrochloride
Standard immunosuppression of the anti-proliferative class.
Other Names:
  • CellCept
  • MMF
Drug: Prednisone
Standard immunosuppression (corticosteroid class).
Other Names:
  • Deltasone
Drug: Azathioprine
Standard immunosuppression of the anti-proliferative class.
Other Names:
  • Imuran
Drug: Tacrolimus
Standard Immunosuppression regimen with Intermediate-Release Tacrolimus.
Other Names:
  • Prograf
  • FK506
  • Intermediate Release Tacrolimus

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety and Tolerability
Time Frame: 6 months
Composite of mortality, allograft failure, potential drug induced liver injury, supra-therapeutic trough levels (>20 ng/mL), sub-therapeutic trough levels (<5 ng/mL), seizures, encephalopathy, thrombotic microangiopathy and serious hyperkalemia associated with use of LCP-tacrolimus, compared to matched historical controls administered IR-tacrolimus.
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Median change in eGFR at 9 months post-transplant.
Time Frame: 9 months
Median change in eGFR from study start to 9 months post-transplantation with patients administered LCP-tacrolimus compared to IR-tacrolimus.
9 months
Headache frequency and severity
Time Frame: 9 months
Quality of life related to headache frequency and severity using the Headache Impact Tool (HIT-6).
9 months
Quality of life related to tremor
Time Frame: 9 months
Quality of life related to tremor as measured by the QUEST tool.
9 months
Incidence of acute cellular rejection
Time Frame: 9 months
Incidence of acute cellular rejection (>= A1) or lymphocytic bronchiolitis (>= B1R)
9 months
Incidence of de novo donor-specific anti-HLA antibodies
Time Frame: 9 months
Incidence of de novo donor-specific anti-HLA antibodies (MFI > 1500) within the first 9 months post-transplant.
9 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Vanderbilt University Medical Center

Collaborators

Veloxis Pharmaceuticals

Investigators

  • Principal Investigator: Anil J Trindade, MD, Vanderbilt University Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2023

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

July 9, 2020

First Submitted That Met QC Criteria

July 9, 2020

First Posted (Actual)

July 14, 2020

Study Record Updates

Last Update Posted (Actual)

January 10, 2024

Last Update Submitted That Met QC Criteria

January 8, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • VEL-IIS-2020-085

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Transplant; Complications

Clinical Trials on Tacrolimus Extended Release Oral Tablet [Envarsus]

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe